Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1091]
News [2721]
Articles [182]
Editorials [9]
Conferences [110]
elearning [25]

TIVO 1 study shows tivozanib an option for renal cell carcinoma

Dr Robert Motzer - Memorial Sloan Kettering Cancer Centre, New York, USA
TIVO 1 study shows tivozanib an option for renal cell carcinoma ( Dr Robert Motzer - Memorial Sloan Kettering Cancer Centre, New York, USA )
25 Feb 2013

Chemo-radiotherapy for bladder cancer

Prof Nick James - University of Birmingham, UK
Chemo-radiotherapy for bladder cancer ( Prof Nick James - University of Birmingham, UK )
25 Feb 2013

Prediction of relapse in stage I nonseminomatous germ cell tumors by CXCL12

Dr Duncan Gilbert - Sussex Cancer Centre, Brighton , UK
Prediction of relapse in stage I nonseminomatous germ cell tumors by CXCL12 ( Dr Duncan Gilbert - Sussex Cancer Centre, Brighton , UK )
25 Feb 2013

New agents and mTOR inhibitors

Dr David Sabatini – Whitehead Institute, Boston, USA
New agents and mTOR inhibitors ( Dr David Sabatini – Whitehead Institute, Boston, USA )
7 Dec 2012

New genetic sub-types of breast, ovarian and prostate cancer

Dr Paul Pharoah – University of Cambridge, UK
New genetic sub-types of breast, ovarian and prostate cancer ( Dr Paul Pharoah – University of Cambridge, UK )
14 Nov 2012

Advances in the treatment of prostate cancer

Prof Malcolm Mason – Cardiff University, UK
Advances in the treatment of prostate cancer ( Prof Malcolm Mason – Cardiff University, UK )
14 Nov 2012

Recent evidence to support the use of aspirin in the treatment of cancer

Dr Ruth Langley – Medical Research Council, London, UK
Recent evidence to support the use of aspirin in the treatment of cancer ( Dr Ruth Langley – Medical Research Council, London, UK )
1 Nov 2012

Advances in advanced renal cell carcinoma from ESMO 2012: Part 1

Prof Tim Eisen - Addenbrooke's Oncology Centre, UK, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, UK, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA
Advances in advanced renal cell carcinoma from ESMO 2012: Part 1 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, UK, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, UK, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )
15 Oct 2012

Advances in advanced renal cell carcinoma from ESMO 2012: Part 3

Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA
Advances in advanced renal cell carcinoma from ESMO 2012: Part 3 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )
13 Oct 2012

Advances in advanced renal cell carcinoma from ESMO 2012: Part 2

Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA
Advances in advanced renal cell carcinoma from ESMO 2012: Part 2 ( Prof Tim Eisen - Addenbrooke's Oncology Centre, Cambridge, Prof Bernard Escudier - Institut Gustave Roussy, France, Dr Thomas Powles - St Bartholomew Hospital, London, Dr Thomas Hutson - Baylor Sammons Cancer Center, USA )
13 Oct 2012

Genes, chromosomes and the treatment of bladder cancer

Dr Jonathan Rosenburg - Memorial Sloan Kettering Cancer Center, New York, USA
Genes, chromosomes and the treatment of bladder cancer ( Dr Jonathan Rosenburg - Memorial Sloan Kettering Cancer Center, New York, USA )
10 Oct 2012

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

Dr Yves Menu – Saint Antoine Hospital, Paris, France
Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST) ( Dr Yves Menu – Saint Antoine Hospital, Paris, France )
9 Oct 2012

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation